Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Cancer Clear all

Conditions: Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer
Interventions: Tissue Biopsy, Magnetic Resonance Imaging (MRI); Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Interventions: Sacituzumab govitecan, Adaptive Radiotherapy; Drug · Radiation
Lead sponsor: Shilpa Gupta, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Pathfinder Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-102; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more

Conditions: Urinary Bladder Neoplasms
Interventions: Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Interventions: Intra-operative Radiation Therapy - IORT; Radiation
Lead sponsor: Xoft, Inc.; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • Long Beach, California + 17 more

Conditions: Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions: Azacitidine; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
Interventions: VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care); Drug · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Phoenix, Arizona • Denver, Colorado • Cumberland, Maryland + 3 more

Conditions: Invasive Breast Carcinoma
Interventions: Best Practice, Exercise Intervention (home walking program and resistance training), Exercise Intervention (home-based Zumba program and resistance training), Exercise Intervention (HIIT program and resistance training), Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration; Other · Behavioral · Device
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Not listed
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: immunologic technique, laboratory biomarker analysis, mass spectrometry; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Muscle Invasive Bladder Cancer
Interventions: Radiation and chemoradiation, Radical cystectomy; Radiation · Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab, Cisplatin, Gemcitabine, Fluorouracil, Mitomycin c, Radical cystectomy, Radiation therapy; Drug · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer, Urothelial Carcinoma Bladder
Interventions: Not listed
Lead sponsor: Pangea Laboratory LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer Survivor, Invasive Breast Carcinoma
Interventions: Physical Activity, Questionnaire Administration, Repetitive Transcranial Magnetic Stimulation, Sham Intervention; Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: Isosulfan Blue, Lymphangiography, Technetium Tc 99m sulfur colloid; Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions: Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy, Tumor Cell-Derived Vaccine Therapy; Drug · Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-200, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 29
States / cities: Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more

Conditions: Bladder Cancer
Interventions: informational intervention, questionnaire administration, management of therapy complications, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: David Latini; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oncologic Surgery, Cancer, Cancer Surgery, Hepatic Cancer, Gastric (Cardia, Body) Cancer, Biliary Tract Cancer, Pancreatic Cancer Resectable, Gynecologic Cancers, Gastrointestinal Cancers, Colorectal Cancer, Minimally Invasive Surgical Procedures
Interventions: Local Anesthesia, Laparoscopic Transversus Abdominis Plane block; Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Cancer, Muscle Invasive Bladder Cancer
Interventions: Avelumab, Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 4 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

MRI and Bladder Cancer Chemotherapy

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Exercise in Improving Health and Quality of Life in Breast Cancer Survivors

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer

Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer

Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases

A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Health-Related Quality of Life in Patients With Bladder Cancer

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)